Multiple myeloma patients undergoing autologous stem cell transplants (ASCT) may strongly benefit from SELLAS‘ WT-1 cancer vaccine, galinpepimut-S, according to recent data from a…
News
GlycoMimetics will present preclinical research at the American Association for Cancer Research (AACR) Annual Meeting 2017, demonstrating the potential of two drug candidates,…
Celyad is ready to enroll patients in its Phase 1 THINK trial in Rosewell Park, N.Y. and the University of Pittsburgh Medical Center in Pennsylvania after gaining…
Patients with relapsed or refractory multiple myeloma who receive a combination of Kyprolis (carfilzomib) and dexamethasone have significantly better survival rates than those receiving Velcade (bortezomib) plus…
A rabbit virus slowed the growth of multiple myeloma in mice, and eradicated the cancer in a fourth of the animals, a study reported. But…
Patients undergoing hematopoietic (donor) stem cell transplants could benefit from treatment with the experimental drug letermovir, which prevents the common viral infection cytomegalovirus (CMV). These results…
One kind of immune cell helps another stay active for years against invaders, a finding that could lead to therapies for autoimmune diseases and certain…
The U.S. Food and Drug Administration has approved the anti-CD20 therapy Revlimid (lenalidomide) as a maintenance therapy for multiple myeloma patients who received an…
Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at lower-volume facilities, according to recent…
The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have failed to respond to treatment.
